Clobazam is a 1,5-benzodiazepine, comprising of B ring nitrogen placed in positions 1 and 5 contrary to 1,4-benzodiazepines. It was first synthesized in 1966. Clobazam is a partial GABA receptor agonist, with anxiolytic, sedative, and anticonvulsant activities. It has been marketed as an anxiolytic since 1975 and an anticonvulsant since 1984. The oral preparation was FDA approved on October 21, 2011.
Clobazam is a Schedule IV controlled substance. Common side effects of clobazam include fever, drowsiness, dizziness, drooling, and constipation. In humans, tolerance to the anticonvulsant effects of clobazam may occur and withdrawal seizures may occur during abrupt or over-rapid withdrawal. Clobazam as with other benzodiazepine drugs can lead to physical dependence and addiction, thus causing benzodiazepine withdrawal syndrome.
The product is currently under development. Samples are available from R&D.
SPECIFICATIONS
| SR. No | Criteria | Limit/Specification |
|---|---|---|
| 1 | Appearance (Color) | White to Almost white |
| 2 | Appearance (Form) | Crystalline Solid |
| 3 | Solubility | Freely soluble in methylene chloride, Sparingly soluble in ethanol, Slightly soluble in water |
| 4 | Solubility (In Water) |
188mg/L (25 °C) |
| 5 | Melting Point | 162-164°C |
| 5 | Density | 1.335 g/cm3 | 6 | Uses | As an adjunctive therapy in Epilepsy |
Other APIs
Website Designed & Developed By: Webtech Softwares Pvt. Ltd. | Digital Marketing Agency
Copyright © 2014-22 Macsen Laboratories.
